Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. (March 2016)

• Record Type: Journal Article
• Authors: Villaruz, Liza C.; Socinski, Mark A.
• Is Part Of: European journal of cancer. Volume 56(2016)
• Page Start: 162
• Page End: 171
• Publication Date: 2016-03
• Subjects: Nab-paclitaxel -- Non-small cell lung cancer (NSCLC) -- Carboplatin -- Neuropathy -- Squamous cell histology -- Elderly; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2015.12.022
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. This approval was based on the results of a phase III clinical trial showing superior response rates compared with solvent-based paclitaxel in combination with carboplatin. This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC. Highlights: Compared with solvent-based paclitaxel and carboplatin, nab-paclitaxel/carboplatin (nab-PC) is associated with superior response rates in newly diagnosed advanced non-small cell lung cancer (NSCLC) patients. Nab-PC appears to be more tolerable from the standpoint of peripheral neuropathy. Nab-PC is particularly effective in patients with advanced NSCLC of squamous cell histology. Nab-PC is associated with a survival advantage in elderly NSCLC patients, an advantage that does not appear to be at the expense of quality of life.